S-1/A: Xcelerate Inc. Files Amended S-1 for Proposed Public Offering and Nasdaq Listing

Xcelerate, Inc. has filed an amended S-1 registration statement detailing its plans for a public offering and subsequent listing on the Nasdaq Capital Market, aiming to fund its healthcare services and products businesses.

Summary

• Xcelerate, Inc., a healthcare services and products company, has filed an amended S-1/A registration statement with the SEC.
• The company is planning a public offering of its common stock with the intention of listing on the Nasdaq Capital Market under the symbol XCRT.
• The offering's proceeds are earmarked for ESN Group product development and marketing, expansion of the Afiya project, and general corporate purposes.
• Xcelerate operates in three sectors: virtual health technology, skin and hair care products, and medical equipment licensing.
• The company acquired a majority interest in Afiya Sasa Africa, LLC (ASA) in July 2023, focusing on AI and virtual health technology in developing countries.
• In July 2023, Xcelerate also acquired a majority interest in the ESN Group, which includes Ceramedx and Earth Science Beauty skin and hair care products.
• The company anticipates a reverse stock split within a range of 1-for-[] to 1-for-[] prior to the completion of the offering.
• The company's common stock is currently quoted on the OTCQB under the symbol XCRT.
• The company has granted the underwriters a 45-day option to purchase additional shares to cover over-allotments.
• The company's independent accountants have expressed a 'going concern' opinion.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company is pursuing growth opportunities and has made strategic acquisitions, it also faces significant financial challenges and risks, including a 'going concern' opinion from its auditors.

Positives

• The company is expanding into high-growth potential markets like virtual health in Africa.
• The acquisition of ESN Group provides an immediate revenue stream and established product lines.
• The company has secured agreements with hospitals in Tanzania, indicating market traction for its virtual health technology.
• The company has a diverse portfolio of patents and licenses in the medical technology space.

Negatives

• The company has a limited operating history and has incurred net losses.
• The company's independent accountants have expressed a 'going concern' opinion.
• The company may require additional capital to fully implement its business plan.
• The company faces intense competition in both the skincare and virtual health markets.
• The company's success depends on the acceptance and adoption of its products and services in new markets.

Risks

• The company's independent accountants have expressed a 'going concern' opinion.
• The company may not be able to achieve profitability.
• The company may require additional funding to satisfy its future capital needs, which may not be available.
• The company is an early-stage company with a business model and marketing strategy still being developed and largely untested.
• The company's officers and directors may be engaged in a range of business activities resulting in conflicts of interest.
• The company's stock price could be extremely volatile and may decline substantially from the public offering price.
• The company may issue additional shares of its common stock or create a new class of securities, including issuance of a new class of preferred stock if it needs to raise additional capital.

Future Outlook

The company anticipates generating revenues from agreements with hospitals in Tanzania approximately 3-4 months following closing of this offering. The company believes that this offering, if successfully completed, will fully mitigate the afore expressed doubt about our ability to continue as a going concern.

Industry Context

The company operates in the growing healthcare services and products market, focusing on telemedicine and skincare. The telemedicine market is experiencing rapid growth, particularly in developing countries, while the skincare market is driven by increasing consumer demand for natural and clinically tested products.

Comparison to Industry Standards

• The document does not provide specific financial metrics or project details that can be directly compared to industry standards.
• The document mentions competitors such as Proctor and Gamble, Johnson and Johnson, Loreal, Babylon (Rwanda only), Agha Khan Pigia Daktar, iPath plus, Lyft Plus and Ada Health, but does not provide a detailed comparison of financial performance or market share.
• The document states that Ceramedx is the first natural alternative to CeraVe, Eucerin, and/or Cetaphil, the leading skincare products on the market, but does not provide specific data to support this claim.

Related Party Transactions

• A significant portion of the funding for the company's operations has been provided by its CEO in the form of interest-free demand loans.
• The company entered into an exclusive world-wide license agreement with Consulting Group of Jocassee, Inc., where one of the company's directors is President.
• The company's principal place of business is provided to it by a company owned and controlled by its CEO, rent-free.

Stakeholder Impact

• Shareholders face potential dilution from future stock offerings.
• Employees may benefit from company growth and expansion.
• Customers in Africa could gain access to improved healthcare services through ASA.
• Suppliers and creditors may be impacted by the company's financial performance and ability to meet its obligations.

Next Steps

• Complete the public offering and secure Nasdaq listing.
• Implement marketing and product development plans for ESN Group.
• Expand and develop ASA operations in Tanzania and other African countries.
• Identify and pursue potential licensing agreements for medical equipment patents.

Key Dates

Keywords

Xcelerate, public offering, Nasdaq, virtual health, skincare, Afiya Sasa, ESN Group, Ceramedx, telemedicine, medical technology